文献速递免疫规划传染病防控与疫情报告

北京≥60岁人群流感疫苗接种对住院保护效果(2016-18)

The effectiveness of influenza vaccination in preventing hospitalizations in elderly in Beijing, 2016-18.
PubMed 文献 · Vaccine · 2019-02-28

该研究采用检测阴性设计,纳入2016/17和2017/18流感季北京9家哨点医院因严重急性呼吸道感染住院的≥60岁患者,从接种登记获取疫苗状态并用RT-PCR检测流感病毒。结果显示2016/17季调整疫苗效果为32.8%(95%CI:-22.0至63.0%),2017/18季对任何流感为4.6%(95%CI:-72.4至47.2%),提示中度至轻度保护。

要点

  • 2016/17季≥60岁SARI住院者调整VE为32.8%(95%CI:-22.0至63.0%)
  • 2017/18季对任何流感调整VE为4.6%(95%CI:-72.4至47.2%)
  • 两季最常见亚型均为甲型H3N2(78.5%和70.6%)

核心结论

  • 流感疫苗在2016/17季对北京≥60岁流感相关住院患者提供中度保护,在2017/18季提供轻度保护。

研究设计与样本

  • 采用检测阴性设计,比较流感阳性与阴性SARI住院患者的接种 odds,并调整发病日历周、年龄和基础疾病。
  • 研究人群为2016/17和2017/18流感季北京9家哨点医院符合SARI定义且住院的患者。
  • 接种状态来自疫苗接种登记,咽部或下呼吸道样本用实时RT-PCR检测甲型和乙型流感病毒。

主要发现

  • 共识别50364例患者;2016/17季≥60岁中流感病例145例、流感阴性对照528例,2017/18季分别为149例和358例。
  • 2016/17季最常见亚型为甲型H3N2(78.5%),2017/18季亦为甲型H3N2(70.6%)。
  • ≥60岁SARI患者中,2016/17季对任何流感病毒的调整VE为32.8%(95%CI:-22.0至63.0%)。
  • 2017/18季调整VE:对任何流感4.6%(95%CI:-72.4至47.2%),对甲型H1N1pdm09 29.2%(95%CI:-92.9至74%),对甲型H3N2 -37.7%(95%CI:-293.8至51.9%),对乙型流感3.6%(95%CI:-113.8至56.5%)。

临床怎么用

  • 对北京≥60岁人群,流感疫苗接种在2016/17季显示中度保护、2017/18季保护轻微,应结合当季流行亚型评估收益。
  • 评估老年人流感疫苗效果时,可采用检测阴性设计并调整发病时间、年龄和基础疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Influenza vaccinations play an important role in preventing influenza related hospitalizations. The objective of this study was to estimate the effectiveness of vaccination in protecting Beijing residents aged ≥60 years from influenza related hospitalizations during the 2016/17 and 2017/18 influenza seasons. METHODS: Patients who met the definition of severe acute respiratory infection (SARI) and were hospitalized in the nine sentinel hospitals in Beijing during the 2016/17 and 2017/18 influenza seasons were identified as the study population. The vaccination status of patients was obtained from a vaccination registry. Real-time reversetranscription polymerasechainreaction (RT-PCR) experiments were conducted to test pharyngeal or lower respiratory tract samples collected from SARI patients for influenza A and B viruses. Vaccine effectiveness (VE) was examined using a test-negative design that compare the odds of vaccination among influenza positives and negatives, adjusting for calendar week of illness onset, age, and underlying medical conditions. RESULTS: We identified 50,364 patients in the study, in which there were 145 influenza cases and 528 influenza-negative controls aged ≥60 years in 2016/17 season and 149 cases and 358 controls aged ≥60 years in 2017/18 season. The most commonly identified subtype among participants was influenza A(H3N2) in 2016/17 and 2017/18 season (78.5% and 70.6%). Among the adults aged ≥60 years, the adjusted VE of vaccination against any influenza virus for serious acute respiratory infection (SARI) patients was 32.8% (95% confidence interval [CI]: -22.0 to 63.0%) in 2016/17 season. While the adjusted VE in 2017/18 season were 4.6% (95% CI: -72.4 to 47.2%) against any types of influenza, 29.2% (95% CI: -92.9 to 74%) against influenza A(H1N1)pdm09, -37.7% (95% CI: -293.8; 51.9%) against influenza A(H3N2) viruses, and 3.6% (95% CI: -113.8 to 56.5%) against influenza B. CONCLUSION: The influenza vaccine provided moderate protection in 2016/17 season and mild protection in 2017/18 season for influenza related inpatients of adults aged ≥60 years in Beijing.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhang D, Zhang Y, Wang Q, et al. The effectiveness of influenza vaccination in preventing hospitalizations in elderly in Beijing, 2016-18. Vaccine. 2019. PMID: 30827734. doi:10.1016/j.vaccine.2019.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。